Imatinib or transplant for chronic myeloid leukaemia?

نویسندگان

  • C Craddock
  • B Augustson
  • S Basu
چکیده

countries that can define their priorities convincingly (but do not have large populations of poor people), funding for corrupt and dictatorial governments that have little regard for their poorest citizens, and the enormous waste of the limited talents of many developing countries that have been spent on inventing new approaches to developing competitive proposals to satisfy yet another under-resourced aid bureaucracy with little chance of success. That Périn and Attaran are urging a repeat of the failed design for the Global Fund that Attaran proposed in his and Sach’s 2001 Lancet article as the basis for allocating donor support for the health sector as a whole, is shameful. If there was ever a need for evidence-based thinking about international health policy to replace ideological befuddlement, Périn and Attaran have demonstrated it in their Viewpoint. Cliff Lenton

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

NICE backs leukaemia drug after manufacturer drops price.

The National Institute for Health and Clinical Excellence has recommended nilotinib (Tasigna) for the firstline treatment of chronic myeloid leukaemia after the manufacturer agreed to reduce the price for the NHS. In final draft guidance NICE also reaffirmed the use of imatinib (Glivec) for firstline treatment of the rare condition that affects around 560 people in the UK each year. Both drugs ...

متن کامل

An update on imatinib mesylate therapy in chronic myeloid leukaemia patients in a teaching hospital in Malaysia.

INTRODUCTION The introduction of imatinib mesylate in 1998 has changed the management of chronic myeloid leukaemia. It is now the first-line therapy for newly diagnosed chronic myeloid leukaemia patients worldwide. However, its long-term survival benefit still needs to be established in clinical setting among Asian patients. METHODS All chronic myeloid leukaemia patients in the chronic phase ...

متن کامل

Analysis of Expression Of SIRT1 Gene In Patients With Chronic Myeloid Leukemia Resistant To Imatinib Mesylate

Background: Chronic myeloid leukemia is a clonal myeloproliferative disease which is characterized by bcr/abl translocation. With the emergence of tyrosine kinase inhibitors such as imatinib mesylate, significant improvement has been made in treatment of this disease. However, drug resistance against this medicine is still an obstacle. SIRT1 is a gene with deacetylase activity which has been de...

متن کامل

Imatinib mesylate-related fatal acute hepatic failure in a patient with chronic myeloid leukaemia and chronic hepatitis B infection.

Imatinib mesylate (Gleevec) is widely-used in the treatment of chronic myeloid leukaemia (CML) and gastrointestinal stromal tumour. Up to four percent of patients treated with imatinib may develop hepatotoxicity, which usually resolves with discontinuation of the drug. We report a 45-year-old Chinese man with CML and chronic hepatitis B virus infection, on imatinib treatment, presenting with he...

متن کامل

A flow-based synthesis of imatinib: the API of Gleevec.

A concise, flow-based synthesis of Imatinib, a compound used for the treatment of chronic myeloid leukaemia, is described whereby all steps are conducted in tubular flow coils or cartridges packed with reagents or scavengers to effect clean product formation. An in-line solvent switching procedure was developed enabling the procedure to be performed with limited manual handling of intermediates.

متن کامل

Evaluation of Thyroid Dysfunction during Imatinib Therapy in Chronic Myeloid Leukemia

Background: Imatinib mesylate is the first generation of Tyrosine kinase inhibitors (TKI) and highly effective in the treatment of chronic myeloid leukemia (CML). We aimed to evaluate thyroid function at baseline and at 1, 3, 6 and 12 months after initiation of Imatinib mesylate therapy in 20 newly diagnosed BCR-ABL positive CML patients. Methods: This study was done during 2013-2014, 20 new c...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:
  • Lancet

دوره 362 9378  شماره 

صفحات  -

تاریخ انتشار 2003